Marinomed Biotech AG (WBO:MARI) Total Current Assets : €7.14 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Marinomed Biotech AG Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Marinomed Biotech AG's total current assets for the quarter that ended in Dec. 2023 was €7.14 Mil.

Marinomed Biotech AG Total Current Assets Historical Data

The historical data trend for Marinomed Biotech AG's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinomed Biotech AG Total Current Assets Chart

Marinomed Biotech AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

15.34

15.40

12.88

14.27

7.14

Marinomed Biotech AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															14.27	11.51	10.03	7.53	7.14

Marinomed Biotech AG Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Marinomed Biotech AG's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.589	+	2.384	+	1.013	+	1.149
	=	7.14

Marinomed Biotech AG's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.589	+	2.384	+	1.013	+	1.149
	=	7.14

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Marinomed Biotech AG (WBO:MARI) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Marinomed Biotech AG's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.589	-	24.748	+	0.75 * 1.403	+	0.5 * 1.013
=	-20.60

Marinomed Biotech AG Total Current Assets Related Terms

Thank you for viewing the detailed overview of Marinomed Biotech AG's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinomed Biotech AG (WBO:MARI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinomed Biotech AG (WBO:MARI) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

93Z:Germany

Address

Hovengasse 25, Korneuburg, AUT, 2100

Website

https://www.marinomed.com

Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generates from the virology segment.

Marinomed Biotech AG (WBO:MARI) Headlines

No Headlines